RxDoctor Payments Data

Larry Gazzini, MD

Internal Medicine · Birmingham, ALNPI 1598874620

Payments from drug & device makers

$9,124in general payments, 2019–2025

Across 602 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$991
  • Pfizer$949
  • Gilead$614
  • Lilly USA, LLC$589
  • Amgen$428
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$9,119100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,124 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$118,450
Medicare patients
221
Services billed
2,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$104,421
TrulicityDulaglutide53$83,940
MounjaroTirzepatide54$72,601
EliquisApixaban41$50,740
RybelsusSemaglutide14$32,281
InvokanaCanagliflozin16$28,184
FarxigaDapagliflozin Propanediol33$24,505
OzempicSemaglutide23$21,820
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,898
XareltoRivaroxaban22$14,251
Victoza 3-PakLiraglutide13$10,690
Breo ElliptaFluticasone/Vilanterol22$10,594
Pravastatin Sodium236$7,422
Losartan Potassium479$7,153
Atorvastatin Calcium469$7,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$589$156,542107 claims
Boehringer IngelheimJardiance$178$104,42184 claims
Novo NordiskRybelsus, Ozempic$1,038$54,10137 claims
PfizerEliquis$949$50,74041 claims
Johnson & JohnsonInvokana, Xarelto$382$42,43538 claims
GSKTrelegy Ellipta, Breo Ellipta$350$26,49339 claims
AstraZenecaFarxiga$122$24,50533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →